International study on inter-reader variability for circulating tumor cells in breast cancer

Breast Cancer Research

Volumn 16, Issue 2, 2014, Pages

  Ignatiadis, Michail ^a   Riethdorf, Sabine ^b   Bidard, François Clement ^c   Vaucher, Isabelle ^c   Khazour, Mustapha ^c   Rothé, Françoise ^a   Metallo, Jessica ^a   Rouas, Ghizlane ^a   Payne, Rachel E ^d   Coombes, Raoul C ^d   Teufel, Ingrid ^e   Andergassen, Ulrich ^f   Apostolaki, Stella ^g   Politaki, Eleni ^g   Mavroudis, Dimitris ^g   Bessi, Silvia ^h   Pestrin, Marta ^h   Di Leo, Angelo ^h   Campion, Michael ⁱ   Reinholz, Monica ⁱ   Perez, Edith ⁱ   Piccart, Martine ^a   Borgen, Elin ^j   Naume, Bjorn ^k   Jimenez, Jose ^l   Aura, Claudia M ^l   Zorzino, Laura ^m   Cassatella, Maria C ^m   Sandri, Maria T ^m   Mostert, Bianca ⁿ   Sleijfer, Stefan ⁿ   Kraan, Jaco ⁿ   Janni, Wolfgang ^o   Fehm, Tanja ^p   Rack, Brigitte ^f   Terstappen, Leon ^q   Repollet, Madeline ^r   Pierga, Jean Yves ^c   Miller, Craig ^r   Sotiriou, Christos ^a   Michiels, Stefan ^s   Pantel, Klaus ^b   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF CRETE   (Greece)

^h HOSPITAL OF PRATO   (Italy)

ⁱ MAYO CLINIC   (United States)

^j Radium Hospital   (Norway)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF ULM   (Germany)

^p HEINRICH HEINE UNIVERSITY   (Germany)

^q Department of Medical Cell BioPhysics ^*  (Netherlands)

^r Veridex LCC   (United States)

^s Department of Biostatistics and Epidemiology Institut Goustave Roussy   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER GRADING; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; CONSENSUS; CONTROLLED STUDY; CYTOPLASM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EUROPE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; INTERRATER RELIABILITY; LABORATORY PERSONNEL; LEUKOCYTE; MAJOR CLINICAL STUDY; METASTASIS; NON METASTATIC BREAST CANCER; PRACTICE GUIDELINE; PROTEIN EXPRESSION; SYSTEMIC THERAPY; UNITED STATES; ARTIFACT; CANCER PATIENT; CLINICAL CLASSIFICATION; CONSENSUS DEVELOPMENT; VERIDEX CONSENSUS; BLOOD; BREAST TUMOR; CELL COUNT; DEVICES; INTERNATIONAL COOPERATION; LABORATORY; METABOLISM; ONCOLOGY; PATHOLOGY; REPRODUCIBILITY; STANDARD; STANDARDS; TUMOR EMBOLISM;

BREAST NEOPLASMS; CELL COUNT; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LABORATORIES; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 84901687402     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3647     Document Type: Article

References (28)

1. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8:329-340. 10.1038/nrc2375, 18404148.
2. Ignatiadis M, Reinholz MM. Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res 2011, 13:222. 10.1186/bcr2906, 3262191, 22078011.
3. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J, Pantel K. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012, 18:5701-5710. 10.1158/1078-0432.CCR-12-1587, 22908097.
4. Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012, 63:199-215. 10.1146/annurev-med-062310-094219, 22053740.
5. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
6. Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008, 19:891-897. 10.1093/annonc/mdm558, 18056915.
7. Liu MC, Mego M, Nakamura S, Nole F, Pierga J, Toi M, Munzone E, Yagata H, Sandri MT, Bidard F, Wang H, Hayes DF, Cristofanilli M. Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). J Clin Oncol 2011, 29:10592.
8. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C, Bidard FC. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012, 23:618-624. 10.1093/annonc/mdr263, 21642515.
9. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M, Pierga JY. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010, 21:729-733. 10.1093/annonc/mdp391, 19850639.
10. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13:688-695. 10.1016/S1470-2045(12)70209-7, 22677156.
11. Rack B, Andergassen U, Janni W, Neugebauer J. CTCs in primary breast cancer (I). Recent Results Cancer Res 2012, 195:179-185. 10.1007/978-3-642-28160-0_16, 22527505.
12. Franken B, de Groot MR, Mastboom WJ, Vermes I, van der Palen J, Tibbe AG, Terstappen LW. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 2012, 14:R133. 10.1186/bcr3333, 23088337.
13. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
14. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV, Terstappen LW. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002, 21:1111-1117.
15. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101:9393-9398. 10.1073/pnas.0402993101, 438987, 15194824.
16. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645. 10.1158/1078-0432.CCR-09-2042, 20406831.
17. Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M, Sotiriou C. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011, 6:e15624. 10.1371/journal.pone.0015624, 3018524, 21264346.
18. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010, 124:403-412. 10.1007/s10549-010-1163-x, 20859679.
19. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013, 59:110-118. 10.1373/clinchem.2012.194258, 23014601.
20. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 2012, 134:283-289. 10.1007/s10549-012-2045-1, 22476856.
21. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart M, Pierga JY. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013, 32:179-188. 10.1007/s10555-012-9398-0, 3655223, 23129208.
22. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 2007, 13:920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
23. Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AG, Maestro M, Gisbert-Criado R, Denton G, de Bono JS, Dive C, Foekens JA, Gratama JW. External quality assurance of circulating tumor cell enumeration using the Cell Search((R)) system: A feasibility study. Cytometry B Clin Cytom 2011, 80:112-118.
24. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007, 71:154-162.
25. Pierga J, Bidard F, Andre F, Petit T, Dalenc F, Delozier T, Romieu G, Bonneterre J, Ferrero J, Kerbrat P, Martin A, Viens P. Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1. J Clin Oncol 2011, 29:10510.
26. Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012, 13:375-384. 10.1016/S1470-2045(12)70049-9, 22377126.
27. Riethdorf S, Mueller V, Mauermann O, Rau T, Loibl S, Eidtmann H, Solbach C, Tesch H, Schrader I, Kittel K, Fehm T, Holms F, Untch M, von Minckwitz G, Pantel K. Changes in circulating tumor and endothelial cells in peripheral blood of patients treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study " GeparQuinto" . Cancer Res 2010, 70:PD04-6.
28. Landis J, Koch G. A one-way component of variance model for categorical data. Biometrics 1977, 33:671-679.